Match each clinical presentation of a patient requiring initiation of antihypertensive therapy to the single most appropriate pharmacological class based on compelling indications and secondary clinical benefits.
- A 42-year-old woman with severe, episodic digital pallor and cyanosis upon cold exposureDihydropyridine calcium channel blocker
- A 58-year-old man with a history of recurrent renal calcium oxalate stonesThiazide diuretic
- A 64-year-old man with stable exertional chest pressure relieved by restCardioselective beta-blocker
- A 35-year-old woman with type 1 diabetes mellitus and persistent microalbuminuriaAngiotensin-converting enzyme inhibitor
Answer
The correct matches align each patient's secondary comorbidity with the mechanistic benefit of specific antihypertensive classes: the patient with Raynaud phenomenon matches with a dihydropyridine calcium channel blocker; the patient with recurrent calcium oxalate stones matches with a thiazide diuretic; the patient with stable angina matches with a cardioselective beta-blocker; and the patient with diabetic nephropathy matches with an angiotensin-converting enzyme inhibitor.
Each correct pairing utilizes the pharmacological mechanism of an antihypertensive class to treat both the high blood pressure and a specific underlying condition. Dihydropyridine calcium channel blockers vasodilate peripheral vessels (benefiting Raynaud phenomenon). Thiazide diuretics enhance distal tubule calcium reabsorption (preventing calcium stones). Beta-blockers slow heart rate and contractility (relieving angina). ACE inhibitors dilate the efferent arteriole (protecting the kidneys in diabetes).
Step-by-Step Solution
Key Concept
Selection of antihypertensive therapy must be individualized based on compelling patient comorbidities and the secondary physiologic mechanisms of the medication.